Wells Fargo analyst Nick Abbott reiterated an Overweight rating and $30.00 price target on Sutro Biopharma (NASDAQ: STRO) after speaking ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE